PVLA Palvella Therapeutics, Inc.

NASDAQ
$146.58

Palvella Therapeutics, Inc. (PVLA) is expected to report earnings on February 4, 2027, before the market open. The consensus earnings estimate is a loss of $1.95 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -12.1% since its last earnings release on November 5, 2026.

Palvella Therapeutics Missed Consensus Estimates
Thursday, November 5, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 7:30 AM ET
Earnings Whisper
-
vs ($1.95)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $161.03

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Palvella Therapeutics, Inc.

Palvella Therapeutics (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.